1. bookVolume 54 (2016): Issue 3 (September 2016)
Journal Details
License
Format
Journal
eISSN
2501-062X
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
access type Open Access

Hepatorenal Syndrome: Diagnosis and Treatment – newsreel –

Published Online: 22 Sep 2016
Volume & Issue: Volume 54 (2016) - Issue 3 (September 2016)
Page range: 143 - 150
Received: 03 Feb 2016
Journal Details
License
Format
Journal
eISSN
2501-062X
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
Abstract

Hepatorenal syndrome (HRS) is defined as renal failure that occurs in the presence of severe acute or chronic liver disease in the absence of underlying renal pathology. Due to the functional nature of the disease and the absence of specific diagnostic markers, HRS diagnosis is determined based on positive criteria associated with excluding other causes of renal failure in patients with liver cirrhosis and ascites. Differentiation from other types of acute or chronic renal disease is extremely difficult and therapeutic options are limited, prophylactic behavior is most appropriate in patients with severe hepatic disease and risk factors for the installation of hepatorenal syndrome.

Highlighting all precipitating factors of acute renal insufficiency and therapeutic modalities in order to minimize adverse events is an important step in improving the follow-up of the patients with liver cirrhosis. The prognosis is reserved especially for type 1 HRS. Liver transplantation is the best option for patients without contraindications. The therapies introduced in recent years, such as vasoconstrictor drugs or transjugular intrahepatic portosystemic shunt are effective methods in the renal function improvement.

Keywords

1. ANGELI P., MERKEL C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008; 48(Suppl 1):S93-103.10.1016/j.jhep.2008.01.010Search in Google Scholar

2. PHAM PT., PHAM PC., RASTOGI A., WILKINSON AH. Review article: current management of renal dysfunction in the cirrhotic patient. Aliment Pharmacol Ther. 2005; 21(8):949-61.10.1111/j.1365-2036.2005.02357.xSearch in Google Scholar

3. CÁRDENAS A., GINÈS P. Hepatorenal syndrome. Clin Liver Dis. 2006; 10(2):371-85.10.1016/j.cld.2006.05.006Search in Google Scholar

4. GINÈS A., ESCORSELL A., GINÈS P., SALÓ J., JIMÉNEZ W., INGLADA L., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993; 105(1):229-36.10.1016/0016-5085(93)90031-7Search in Google Scholar

5. ARROYO V., TERRA C., GINÈS P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007; 46(5):935-46.10.1016/j.jhep.2007.02.001Search in Google Scholar

6. TSOCHATZIS EA., BOSCH J., BURROUGHS AK. Liver cirrhosis. Lancet. 2014; 383(9930):1749-61.10.1016/S0140-6736(14)60121-5Search in Google Scholar

7. ARROYO V., GINÈS P., GERBES AL., DUDLEY FJ., GENTILINI P., LAFFI G., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996; 23(1):164-76.10.1002/hep.510230122Search in Google Scholar

8. SALERNO F., GERBES A., GINÈS P., WONG F., ARROYO V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007; 56(9):1310-8.Search in Google Scholar

9. CHOLONGITAS E., CALVARUSO V., SENZOLO M., PATCH D., SHAW S., O'BEIRNE J., et al. RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol. 2009; 24(10):1639-47.10.1111/j.1440-1746.2009.05908.xSearch in Google Scholar

10. MYERS RP., LEE SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 2000; 6(4 Suppl 1):S44-52.10.1002/lt.500060510Search in Google Scholar

11. BERNARDI M., RUBBOLI A., TREVISANI F., CANCELLIERI C., LIGABUE A., BARALDINI M., et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol. 1991; 12(2):207-16.10.1016/0168-8278(91)90940-DSearch in Google Scholar

12. MONCRIEF K., KAUFMAN S. Splenic baroreceptors control splenic afferent nerve activity. Am J Physiol Regul Integr Comp Physiol. 2006; 290(2):R352-6.10.1152/ajpregu.00489.200516210416Search in Google Scholar

13. GUARNER C., SORIANO G., TOMAS A., BULBENA O., NOVELLA MT., BALANZO J., et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993; 18(5):1139-43.10.1002/hep.1840180520Search in Google Scholar

14. ANGELI P. Hepatorenal syndrome. In: Vincent J-L 2006 Yearbook of Intensive Care and Emergency Medicine. Ed. Springer- Verlag, Berlin, 2006; p. 661-70.10.1007/3-540-33396-7_61Search in Google Scholar

15. FERNÁNDEZ J., NAVASA M., PLANAS R., MONTOLIU S., MONFORT D., SORIANO G., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007; 133(3):818-24.10.1053/j.gastro.2007.06.06517854593Search in Google Scholar

16. DAGHER L., MOORE K. The hepatorenal syndrome. Gut. 2001;4 9(5):729-37.10.1136/gut.49.5.729172849211600480Search in Google Scholar

17. NIETSCH HH. Management of portal hypertension. J Clin Gastroenterol. 2005; 39(3):232-6.10.1097/01.mcg.0000152783.22266.3515718866Search in Google Scholar

18. GENZINI T., TORRICELLI FC. Hepatorenal syndrome: an update. Sao Paulo Med J. 2007; 125(1):50-6.10.1590/S1516-31802007000100010Search in Google Scholar

19. SUZUKI H., STANLEY AJ. Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome. QJM. 2001; 94(6):293-300.10.1093/qjmed/94.6.29311391027Search in Google Scholar

20. KASHANI A., LANDAVERDE C., MEDICI V., ROSSARO L. Fluid retention in cirrhosis: pathophysiology and management. QJM. 2008; 101(2):71-85.10.1093/qjmed/hcm12118184668Search in Google Scholar

21. GINÈS P., TORRE A., TERRA C., GUEVARA M. Review article:pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther. 2004; 20(Suppl 3):57-62; discussion 63-4.10.1111/j.1365-2036.2004.02115.x15335404Search in Google Scholar

22. GINÈS P., CÁRDENAS A., ARROYO V., RODÉS J. Management of cirrhosis and ascites. N Engl J Med. 2004; 350(16):1646-54.10.1056/NEJMra03502115084697Search in Google Scholar

23. MARRERO J., MARTINEZ FJ., HYZY R. Advances in critical care hepatology. Am J Respir Crit Care Med. 2003; 168(12):1421-6.10.1164/rccm.200303-361UP14668256Search in Google Scholar

24. RUNYON BA., AASLD PRACTICE GUIDELINES COMMITTEE. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49(6):2087-107.10.1002/hep.2285319475696Search in Google Scholar

25. SOLANKI P., CHAWLA A., GARG R., GUPTA R., JAIN M., SARIN SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003; 18(2):152-6.10.1046/j.1440-1746.2003.02934.x12542598Search in Google Scholar

26. DUNDAR HZ., YILMAZLAR T. Management of hepatorenal syndrome. World J Nephrol. 2015; 4(2): 277-286.10.5527/wjn.v4.i2.277441913825949942Search in Google Scholar

27. MARTÍN-LLAHÍ M., PÉPIN MN., GUEVARA M., DIAZ F., TORRE A., MONESCILLO A. et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008; 134(5):1352-9.10.1053/j.gastro.2008.02.02418471512Search in Google Scholar

28. KALAMBOKIS G., ECONOMOU M., FOTOPOULOS A., AL BOKHARHII J., PAPPAS C., KATSARAKI A., et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005; 100(4):879-85.10.1111/j.1572-0241.2005.40899.x15784036Search in Google Scholar

29. DAVENPORT A., AHMAD J., AL-KHAFAJI A., KELLUM JA., GENYK YS., NADIM MK. Medical management of hepatorenal syndrome. Nephrol Dial Transplant. 2012; 27(1):34-41.10.1093/ndt/gfr73622287700Search in Google Scholar

30. TURBAN S., THULUYATH PJ., ATTA MG. Hepatorenal syndrome. World J Gastroenterol. 2007; 13(30):4046-55.10.3748/wjg.v13.i30.4046420530417696221Search in Google Scholar

31. LOW G., ALEXANDER GJ., LOMAS DJ. Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract. 2015; 2015:207012.10.1155/2015/207012430636425649410Search in Google Scholar

32. VOLK ML., MARRERO JA. Advances in critical care hepatology. Minerva Anestesiol. 2006; 72(5):269-81.Search in Google Scholar

33. KAPTANOGLU L., BLEI AT. Current status of liver support systems. Clin Liver Dis. 2000; 4(3):711-29, 34. BRENSING KA., TEXTOR J., PERZ J., SCHIEDERMAIER P., RAAB P., STRUNK H., et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000; 47(2):288-95.10.1136/gut.47.2.288Search in Google Scholar

35. SEN S., MOOKERJEE RP., DAVIES NA., WILLIAMS R., JALAN R. Review article: the molecular adsorbents recirculating system (MARS) in liver failure. Aliment Pharmacol Ther. 2002; 16(Suppl 5):32-8.10.1046/j.1365-2036.16.s5.5.xSearch in Google Scholar

36. WIKLUND RA. Preoperative preparation of patients with advanced liver disease. Crit Care Med. 2004; 32(4 Suppl):S106-15.10.1097/01.CCM.0000115624.13479.E6Search in Google Scholar

37. SOLIS-HERRUZO JA., DURAN A., FAVELA V., CASTELLANO G., MADRID JL., MUÑOZ-YAGÜE MT., et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol. 1987; 5(2):167-73.10.1016/S0168-8278(87)80569-XSearch in Google Scholar

38. TANDON P., BAIN VG., TSUYUKI RT., KLARENBACH S. Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials. Aliment Pharmacol Ther. 2007; 25(9):1017-28.10.1111/j.1365-2036.2007.03303.x17439502Search in Google Scholar

39. ALESSANDRIA C., OZDOGAN O., GUEVARA M., RESTUCCIA T., JIMÉNEZ W., ARROYO V., et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005; 41(6):1282-9.10.1002/hep.2068715834937Search in Google Scholar

40. SCHEPKE M., APPENRODT B., HELLER J., ZIELINSKI J., SAUERBRUCH T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int. 2006; 26(7):834-9. 10.1111/j.1478-3231.2006.01302.x16911466Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo